The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma by Heider, M. et al.
ArticleThe IMiD target CRBN determines HSP90 activity
toward transmembrane proteins essential in
multiple myelomaGraphical AbstractHighlightsd CRBN functions as a transmembrane protein-specific co-
chaperone of HSP90
d Disruption of CRBN-HSP90 interaction determines the anti-
tumor activity of IMiDs
d The CD98hc/LAT1 complex is a central target of IMiDs in
multiple myeloma
d CD98hc-Anticalin is a theranostic tool in multiple myelomaHeider et al., 2021, Molecular Cell 81, 1170–1186
March 18, 2021 ª 2021 The Author(s). Published by Elsevier Inc
https://doi.org/10.1016/j.molcel.2020.12.046Authors
Michael Heider, Ruth Eichner,







Heider et al. investigate the molecular
function of immunomodulatory drugs
(IMiDs) and describe their target, CRBN,
as a transmembrane protein (TP)-specific
co-chaperone of the HSP90-AHA1 axis.
By disrupting CRBN-HSP90 interaction,
IMiDs lead to destabilization of various
TPs as CD98hc/LAT1, which serve as




The IMiD target CRBN determines
HSP90 activity toward transmembrane
proteins essential in multiple myeloma
Michael Heider,1,2 Ruth Eichner,1,2 Jacob Stroh,1,2 Volker Morath,3 Anna Kuisl,1,2 Jana Zecha,4,5 Jannis Lawatscheck,6
Kheewoong Baek,7 Anne-Kathrin Garz,1 Martina Rudelius,8 Friedrich-Christian Deuschle,9 Ulrich Keller,5,10
Simone Lemeer,4 Mareike Verbeek,1 Katharina S. Götze,1,5 Arne Skerra,9 Wolfgang A. Weber,3,5 Johannes Buchner,6
Brenda A. Schulman,7 Bernhard Kuster,4,5 Vanesa Fernández-Sáiz,1,2,11,* and Florian Bassermann1,2,5,11,12,*
1Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
2TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany
3Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
4Department of Proteomics and Bioanalytics, Technical University of Munich, 85354 Freising, Germany
5German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
6Center for Integrated Protein Science at the Department of Chemistry, Technical University of Munich, 85748 Garching, Germany
7Department of Molecular Machines and Signaling, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
8Institute of Pathology, Ludwig-Maximilians University, 80337 Munich, Germany
9Lehrstuhl f€ur Biologische Chemie, Technical University of Munich, 85354 Freising, Germany
10Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité – Universit€atsmedizin Berlin, 12200
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https://doi.org/10.1016/j.molcel.2020.12.046SUMMARYThe complex architecture of transmembrane proteins requires quality control (QC) of folding, membrane
positioning, and trafficking as prerequisites for cellular homeostasis and intercellular communication. How-
ever, it has remained unclear whether transmembrane protein-specific QC hubs exist. Here we identify cer-
eblon (CRBN), the target of immunomodulatory drugs (IMiDs), as a co-chaperone that specifically determines
chaperone activity of HSP90 toward transmembrane proteins bymeans of counteracting AHA1. This function
is abrogated by IMiDs, which disrupt the interaction of CRBN with HSP90. Among the multiple transmem-
brane protein clients of CRBN-AHA1-HSP90 revealed by cell surface proteomics, we identify the amino
acid transporter LAT1/CD98hc as a determinant of IMiD activity in multiple myeloma (MM) and present an
Anticalin-based CD98hc radiopharmaceutical for MM radio-theranostics. These data establish the CRBN-
AHA1-HSP90 axis in the biogenesis of transmembrane proteins, link IMiD activity to tumor metabolism,
and nominate CD98hc and LAT1 as attractive diagnostic and therapeutic targets in MM.INTRODUCTION
Faithful biogenesis of transmembrane proteins (TPs) is vital for
cellular homeostasis, adhesion, migration, and intercellular
communication (Guna and Hegde, 2018). Aberrant TPs have
been established as cancer hallmarks and are successfully tar-
geted by immunotherapeutic and molecular cancer treatments
(Lin et al., 2019). Central tasks in TP biogenesis include the
folding of extra-membrane domains as well as membrane inser-
tion of the hydrophobic transmembrane domains, thereby avoid-
ing aggregation and erroneous interactions (Cymer et al., 2015;
Guna and Hegde, 2018). Cytoplasmic chaperone machineries
that specialize on TP quality control would be considered central1170 Molecular Cell 81, 1170–1186, March 18, 2021 ª 2021 The Auth
This is an open access article under the CC BY-NC-ND license (http://to these processes, yet their identity remains largely unknown.
One example marks the quality control of CF-transmembrane
conductance regulator (CFTR). Here, a specific mutation
(DF508) results in defective folding and trafficking of CFTR
from the endoplasmic reticulum (ER) to the plasma membrane,
which is considered to be the molecular cause of cystic fibrosis
(CF) (Goetz and Ren, 2019; Kerem et al., 1989). The underlying
mechanism is a failure of this mutant to pass heat shock protein
of 90 kDa (HSP90)-dependent protection/folding with the conse-
quence of sorting to the ER-associated degradation (ERAD)
pathway. Downregulation of the activator of HSP90 ATPase ac-
tivity 1 (AHA1) was shown to rescue cell surface expression of
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quality control (Koulov et al., 2010; Retzlaff et al., 2010; Wang
et al., 2006).
AHA1 is the most potent ATPase activity stimulator of HSP90,
an essential chaperone that facilitates the maturation, stability,
and activity of several hundred client proteins (Taipale et al.,
2012; Schopf et al., 2017; Wolmarans et al., 2016). AHA1 pro-
motes the formation of the N-terminally dimerized, closed state
of HSP90 and binds to HSP90 in the middle domain as well as
in the ATP-binding N-terminal domain in an asymmetric manner,
with one AHA1 molecule per HSP90 dimer being sufficient to
stimulate the ATPase activity of the HSP90 dimer (Meyer et al.,
2004; Retzlaff et al., 2010). In addition, tyrosine phosphorylation
of AHA1 has been suggested to increase HSP90 ATPase activity
(Dunn et al., 2015). Despite these insights, it has remained un-
clear how specific activity of the AHA1-HSP90 nexus toward
TPs is procured.
Cereblon (CRBN) is the primary target by which immunomod-
ulatory drugs (IMiDs) such as thalidomide and its derivatives le-
nalidomide and pomalidomidemediate their anti-tumor and tera-
togenic activities (Ito et al., 2010; Lopez-Girona et al., 2012;
Zhu et al., 2011). IMiDs have evolved as key treatment modalities
for different hematological malignancies, particularly multiple
myeloma (MM), mantle cell lymphoma, and del(5q) myelodys-
plastic syndromes (Raza et al., 2017). CRBN has been character-
ized as a substrate-recruiting determinant of the CUL4-RBX1-
DDB1 ubiquitin ligase complex (CRL4) that becomes re-directed
toward neo-substrates such as IKZF1/3 and CK1a by certain
IMiDs, thereby promoting their ubiquitylation and proteasomal
degradation (Fischer et al., 2014; Gandhi et al., 2014; Krönke
et al., 2014, 2015; Lu et al., 2014; Zhu et al., 2014). This has
led to the development of IMiD-based proteolysis-targeting
chimeras (PROTACs), which mediate interaction between
CRL4CRBN and typically undruggable neo-targets to induce their
degradation (Winter et al., 2015). However, the pleiotropic anti-
tumor effects of IMiDs, their adverse effects such as teratoge-
nicity and neurotoxicity, and most important their striking syn-
ergy with proteasome inhibitors (PIs) in MM suggest additional
mechanisms of action. Along this line, the structure of CRBN,
which comprises a large LON domain shared with Clp family
chaperones and Lon proteases (Smith et al., 1999), next to theFigure 1. Cell surface proteomics reveal a broad effect of IMiDs on tra
CRBN clients
(A) Quantitative cell surface proteome of MM1s cells treated with lenalidomide
subjected to treatment with 10 mM lenalidomide or DMSO for 48 h, followed by ce
(MS) analysis. Plasma membrane proteins (according to Gene Ontology cellular
members are marked by a yellow dot. Potential interactors of CRBN identified b
(B) Representative immunoblot analysis of MM1S cells that were treatedwith DMS
(Thal) for 72 h.
(C) Representative immunoblot analysis of MM1SWT or MM1S with CRISPR-Cas
(D) Representative immunofluorescence images of HeLa cells that were transfecte
the indicated short hairpin RNAs (shRNAs). Cells were stained with antibodies to
10 mm. Quantification and confirmation of knockdown are presented in Figure S1
(E) Immunoprecipitation (IP) of FLAG-tagged LAT1 from HEK293T cells. Immuno
bodies to the indicated proteins.
(F) IP of FLAG-CD98hc from HEK293T cells. Immunoblot analysis of whole-cell e
(G) IP of FLAG-CRBNWT or CRBNYW/AA from CRBN/ HEK293T co-expressing L
harvest and immunoblot analysis.
1172 Molecular Cell 81, 1170–1186, March 18, 2021hydrophobic pocket of the thalidomide binding domain (TBD),
suggests functions beyond ubiquitin ligase activity. Indeed, we
previously found CRBN to exist in ubiquitin ligase-independent
complexes, where it stabilizes two TPs, CD147 (also known as
basigin) and monocarboxylate transporter 1 (MCT1) (Eichner
et al., 2016). We further demonstrated that IMiDs interfere with
this function of CRBN in a competitive manner to mediate anti-
tumor and teratotoxic effects (Eichner et al., 2016). However, it
has remained unclear how CRBN confers such quality control
functions toward client proteins andwhether CRBNhas other cli-
ents whose functional loss may contribute to IMiD efficacy.
Here, we set out to study the underlying mechanism of CRBN
quality control activity. Starting from an approach that combined
unbiased cell surface proteomics with functional CRBN interac-
tome screens, we identified a global TP-specific chaperone
network comprising CRBN, HSP90, and AHA1. Herein, CRBN
regulates HSP90 function by antagonizing AHA1, which allows
correct folding and maturation of TPs. Among the various novel
CRBN/HSP90/AHA1 client candidates, we specify the amino
acid transporter complex LAT1 (SLC7A5)/CD98hc (SLC3A2) as
a new vulnerability inMM,which becomes destabilized and inac-
tivated upon IMiD treatment. We thus link IMiD activity to tumor
metabolism and characterize CD98hc as target for radio-thera-
nostic approaches.
RESULTS
Cell surface proteomics reveal a broad effect of IMiDs
on TP abundance and specify CD98hc/LAT1 as novel
CRBN clients
To start investigating the impact of IMiDs on TPs, we performed
quantitative unbiased proteomic screens of the MM cell surface
proteome using cell surface biotinylation, streptavidin affinity pu-
rification, and mass spectrometry (Figures 1A, S1A, and S1B).
Strikingly, we observed broad alterations of cell surface protein
abundance in response to lenalidomide treatment (Figure 1A).
We cross-validated these results with our previous CRBN inter-
actome dataset (Eichner et al., 2016) in order to distinguish direct
CRBN clients. This approach yielded CD98hc (CD98 heavy
chain) as the most significant hit that becomes destabilized
upon IMiD treatment and binds to CRBN (Figure 1A; Figure S1C).nsmembrane protein abundance and specify CD98hc/LAT1 as novel
versus solvent. MM1S cells were cultured in SILAC and control medium and
ll surface biotinylation, streptavidin affinity purification, and mass spectrometry
component [GOCC]) are depicted by blue circles. Solute carrier protein family
y tandem-affinity purification and MS are circled in red.
O, 10 mM lenalidomide (Len), 1 mMpomalidomide (Pom), or 100 mM thalidomide
9-mediated homozygous deletion of CRBN (clones T11 and T21).
d with constructs encoding both HA-CD98hc and FLAG-LAT1 and expressing
HA (green) and FLAG (red), and DNA was stained with DAPI (blue). Scale bars,
E.
complexes and respective whole-cell extracts (WCE) were probed with anti-
xtracts and immunocomplexes was performed as indicated.
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plex with LAT1, which preferentially transports neutral branched
or aromatic amino acids (Yan et al., 2019). LAT1 expression
levels increase with progression of plasma cell disorders and
have been associated with high proliferation and poor prognosis
in MM patients (Bolzoni et al., 2016; Isoda et al., 2014).
To validate the screen, we treated MM cells with thalidomide,
lenalidomide, and pomalidomide and observed a substantial
destabilization of CD98hc and LAT1 (Figure 1B). We therefore
went on to investigate CD98hc/LAT1 as potential novel CRBN-
dependent IMiD target proteins. CRISPR-Cas9-mediated deple-
tion of CRBN led to reduced protein abundance of CD98hc and
LAT1 (Figure 1C). Unchanged or elevated CD98hc and LAT1
mRNA levels upon lenalidomide treatment confirmed a post-
transcriptional mechanism independent of the CRL4CRBN neo-
substrate transcription factors IKZF1/3 (Figure S1D). In addition,
depletion of CRBN led to subcellular mis-localization of the
CD98hc/LAT1 complex and cytoplasmic accumulation at the
ER/Golgi, indicative of protein misfolding (Figures 1D, S1E,
S6F, and S6G). We further found specific and direct interaction
of CRBN with CD98hc/LAT1 (Figures 1E, 1F, and S1F) and map-
ped the binding site to the N-terminal intracellular regions of
CD98hc and LAT1 (Figure S1F). The IMiD binding-defective
mutant CRBNYW/AA (mutation of Tyr384 and Trp386 to Ala) (Ito
et al., 2010) failed to interact with CD98hc and LAT1, and IMiD
treatment abrogated the interaction of CRBN with CD98hc and
LAT1, suggesting that IMiDs compete with these TPs for binding
to CRBNs TBD (Figures 1G and S1G).
Together, our cross-validated, unbiased screens and
biochemical experiments identify the CD98hc/LAT1 complex
as a new CRBN interactor that becomes destabilized upon
IMiD treatment.
CRBN interacts with the ATP-bound conformation
of HSP90
We next elucidated the mechanism by which CRBN mediates
quality control activity toward its client proteins. Further interro-
gation of the CRBN interactome revealed AHA1 as a specific in-
teractor of CRBN (Figure S1C). We therefore hypothesized that
CRBNmay be involved in the HSP90-AHA1 chaperone complex.
Indeed, we found AHA1 and HSP90a to specifically interact with
endogenous CRBN in MM cells (Figures 2A and S2A). Impor-
tantly, we ruled out the possibility of CRBN being an HSP90
client. Although treatment of MM cells with different HSP90 in-
hibitors destabilized the HSP90 client glucocorticoid receptorFigure 2. CRBN interacts with the ATP-bound conformation of HSP90
(A) Endogenous IP of CRBN from U266 cells and analysis of co-purified endoge
exposure; SE, short exposure.
(B) IP analysis of different FLAG-HSP90⍺ mutants transfected into HEK293T c
mutations (left).
(C) IP analysis of FLAG-HSP90⍺ transfected into HEK293T cells. Lysis and IP wa
(D) Sequential FLAG/HA IP from HEK293T WCE transfected with the indicated H
and used for an HA IP, resulting in complexes consisting of one FLAG- and one
unmutated promoters; in the third lane, one protomer carries a V410E mutation.
(E) IP analysis of FLAG-HSP90⍺ transfected into CRBN/ HEK293T WCE recon
lenalidomide (50 mM), 17-AAG (1 mM), or DMSO for 24 h prior to harvest.
(F) Quantification of IP analysis presented in (E) (n = 3 independent experiments)
Data are mean ± SD. **p < 0.01 and ***p < 0.001 by one-sample t test.
1174 Molecular Cell 81, 1170–1186, March 18, 2021in a concentration- and time-dependent manner and induced
HSP70 (Sittler et al., 2001), CRBN levels remained stable (Fig-
ures S2B and S2C) and did not accumulate in the insoluble frac-
tion (Figure S2D).
Using bidirectional mapping studies, we found CRBN to
interact with the middle and C-terminal domains of HSP90 (Fig-
ures S3A and S3B) and HSP90 to bind to the LON domain and
DDB1-binding region of CRBN (Figures S3C–S3F). Notably,
HSP90 also co-precipitated with the IMiD binding-defective
mutant CRBNYW/AA (Figure S3C).
To investigate the relation of CRBN binding to the HSP90
folding cycle, we made use of mutants that keep the HSP90
dimer locked in the N-terminally closed (HSP90E47A) or open
(HSP90D93A) state (Panaretou et al., 2002). We found CRBN to
preferentially interact with the closed conformation, a pattern
that is shared with AHA1 and p23 (Figure 2B) (Ali et al., 2006;
Meyer et al., 2004). A point mutation in the middle domain of
HSP90 (HSP90V410E) (Retzlaff et al., 2010) abrogated the
CRBN-HSP90 interaction, thus further supporting binding of
CRBN with the HSP90 middle domain (Figure 2B). Molybdate
stabilizes the nucleotide-bound state of the HSP90 dimer and
has been shown to increase the interaction of HSP90 with its
conformation-specific co-chaperones p23 and AHA1 (Sullivan
et al., 1997; Sun et al., 2015). Indeed, addition of molybdate to
cell extracts markedly stabilized the CRBN-HSP90 interaction,
thus confirming conformation-specific binding (Figures 2C and
S3G). In contrast, the interaction of HSP90 with the proposed
client proteins CD98hc or LAT1 was not changed by molybdate
(Figures S3H and S3I). To investigate if CRBN binds to both or
just one protomer within the HSP90 dimer, we chose an estab-
lished approach based on overexpressing either HA-tagged
and FLAG-tagged HSP90WT protomers or HA-HSP90WT and
FLAG-HSP90V410E mutant protomers (abrogating CRBN and
AHA1 binding to HSP90) (Retzlaff et al., 2010; Woodford et al.,
2017). Using sequential FLAG and HA immunoprecipitation
(IP), we isolated HSP90 dimers consisting of either a wild-type
HA-HSP90WT and a FLAG-HSP90WT protomer (Figure 2D, lane
2) or a wild-type HA-HSP90WT and a mutated FLAG-HSP90V410E
protomer (Figure 2D, lane 3). As opposed to AHA1, which has
been shown to bind asymmetrically to the HSP90 molecule
and require only one wild-type protomer, (Retzlaff et al., 2010),
CRBN required two wild-type HSP90WT protomers for interac-
tion (Figure 2D).
Next, we investigated the impact of IMiDs and HSP90 inhibi-
tors on the HSP90-CRBN interaction. Strikingly, lenalidomidenous proteins as indicated. The asterisk marks an unspecific band. LE, long
ells (right). Models of HSP90 dimer conformations induced by the indicated
s performed in the absence or presence of 20 mM sodium molybdate.
SP90⍺ constructs. After lysis and FLAG IP, bait was eluted with FLAG peptide
HA-tagged HSP90 protomer. The second lane contains complexes with both
stituted with CRBNWT or CRBNYW/AA as indicated. Cells were pretreated with
.
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interaction with the IMiD binding-defective mutant CRBNYW/AA
remained unaffected (Figures 2E, 2F, S4A, and S4B). The
HSP90 inhibitor geldanamycin (GA) mimics an ADP-bound state,
thus inhibiting ATPase activity and locking the chaperone cycle
in the early complex (Neckers, 2003; Zhang et al., 2008). Notably,
treatment with the GA analog 17-N-allylamino-17-demethoxy-
geldanamycin (17-AAG) suppressed HSP90 association with
both CRBNWT and CRBNYW/AA, thus confirming the conforma-
tion-specific interaction (Figures 2E and 2F).
Together, these findings suggest that CRBN specifically inter-
acts with the middle domain of the nucleotide bound, N-termi-
nally closed state of the HSP90a dimer via its LON domain. At
the same time, IMiD binding to the YW motif containing hydro-
phobic pocket of CRBN abrogates HSP90 association with the
LON domain of CRBN.
CRBN modulates HSP90-AHA1 activity toward client
proteins
Because HSP90 and AHA1 have been implicated in the folding of
CFTR (Koulov et al., 2010; Wang et al., 2006), we reasoned that
CRBN may exert its stabilizing effects on the identified TPs via
modulation of this axis. Importantly, a previous study on the
phosphorylation-dependent interactome of AHA1 found CRBN
to preferentially interact with a phospho-mimic form of AHA1
(AHA1Y223E) (Wolfgeher et al., 2015). Phosphorylation of AHA1
at Y223 enhances binding to HSP90, thereby leading to
increased HSP90 ATPase activity and compromised folding of
CFTR (Dunn et al., 2015). To test if CRBN affects the HSP90-
AHA1 interplay, we first confirmed increased binding between
AHA1Y223E and CRBN (Figure 3A). Surprisingly, in contrast to
HSP90, lenalidomide treatment did not affect the CRBN-AHA1
interaction, suggesting that CRBN additionally binds to AHA1 in-
dependent of HSP90 (Figures 3B and S4C). The introduction of
the AHA1E67K mutation, which disrupts HSP90 binding (Meyer
et al., 2004), did also not alter AHA1-CRBN interaction (Figures
3C and S4D), and lenalidomide did not change the AHA1-
HSP90 interaction (Figure S4E). We also excluded the possibility
of CRBN indirectly interacting with HSP90 via AHA1 by perform-
ing interaction studies upon AHA1 depletion (Figures 3D and
S4F). Together, these data suggest that CRBN independently
binds to both AHA1 and HSP90.
Next, we tested the effect of CRBN on the stability of CFTR.
Strikingly, forced expression of CRBN reversed the negative
impact of AHA1 on CFTR protein stability, whereas lenalidomide
abrogated this effect (Figures 3E and 3F). Both IMiD and TP bind-
ing-defective (CRBNYW/AA) as well as DDB1 and HSP90 binding-
defective (CRBNDmid) mutants had no effect on the AHA1-
induced CFTR destabilization, excluding any unspecific effects
of forced CRBN expression (Figure 3E). Importantly, CRBNYW/
AA and lenalidomide treatment showed reduced CRBN binding
to CFTR (Figure S4G), which is in line with our data on
CD98hc/LAT1 (Figures 1G and S1G).
To investigate whether CRBN directly regulates the ATPase
activity of HSP90 in vitro, we determined the impact of CRBN
on HSP90-AHA1, applying an assay that detects ATP hydrolysis
(Dunn et al., 2015). Strikingly, addition of CRBN to HSP90-AHA1
complexes dramatically reduced ATP hydrolysis, while additionof lenalidomide restored HSP90 ATPase activity (Figures 3G
and S4H). In a second approach, CRBN was purified together
with DDB1 from insect cells (Figure S4I). Addition of this complex
to HSP90-AHA1 also reduced ATP hydrolysis significantly,
which could be reversed by lenalidomide (Figure S4J). Validity
was ascertained by addition of the HSP90 inhibitor 17-AAG
(Figure S4K).
Together, these data identify CRBN as an HSP90-AHA1 co-
chaperone, which counteracts the negative effect of AHA1 on
client protein stability by attenuating HSP90’s ATPase activity.
Although CRBN allows sufficient HSP90 client dwelling time
and client folding, IMiD treatment abrogates CRBN binding to
HSP90 and reverses its stabilizing effect.
CRBN is a TP-specific co-chaperone of the HSP90-
AHA1 axis
We next elucidated whether the stabilizing effect of CRBN to-
ward CD98hc and LAT1 results from modulation of HSP90
chaperoning activity and if this HSP90 function extends to a
larger panel of TPs. First, we treated MM cells with lenalidomide
and the HSP90 inhibitor 17-AAG and analyzed different TPs
identified in our surface screen as well as non-TP HSP90 clients.
Importantly, both lenalidomide and 17-AAG destabilized all
probed TPs, including CD98hc and LAT1 as well as CD147,
MCT1, and CFTR (Figure 4A). In contrast, all non-TPs were de-
stabilized only by 17-AAG and remained unaffected by IMiD
treatment, indicating that IMiD effects are restricted to TPs (Fig-
ure 4A). Indeed, knockdown of CRBN destabilized only TPs,
whereas non-TPs remained unaltered (Figure S5A). Moreover,
we found these TPs to interact with both CRBN and HSP90 (Fig-
ures S5B and S5C), whereas non-TP HSP90 clients did not co-
immunoprecipitate with CRBN, with the exception of CUL4A
and DDB1, which are components of the CRL4CRBN ligase (Fig-
ures S5D and S5E).
We next investigated the impact of the CRBN-HSP90-AHA1
axis on CD98hc/LAT1, the top-scoring hit from our cell surface
screen. First, we confirmed time- and dose-dependent destabi-
lization of both proteins upon 17-AAG treatment (Figures S6A–
S6C). Thereafter, we investigated the effects of HSP90 inhibition
and IMiD treatment on the subcellular localization of CD98hc/
LAT1. Both drugs impaired plasma membrane localization while
leading to an accumulation at the ER and Golgi, comparable with
the effects upon CRBN depletion and typical for misfolded pro-
teins (Figures 1D, S1E, 4B, and S6D–S6G). In a further effort, we
confirmed and mapped the binding of CRBN and HSP90 to the
intracellular N-terminal domains of CD98hc and LAT1 (Fig-
ure S6H), studied maturation-dependent interaction by blocking
de novo protein synthesis with cycloheximide (CHX) and found
preferential binding of CRBN and HSP90 to newly synthesized
CD98hc and LAT1 (Figures 4C and 4D).
Finally, we determined whether AHA1 has an impact on our
novel HSP90 TP clients. Next to stabilization of CFTR, which is
in line with previous findings (Wang et al., 2006), AHA1 silencing
showed the same stabilizing effect toward CD98hc/LAT1 and
CD147/MCT1 (Figure 4E). In further support of an important
role of AHA1 on the stability of these TPs, a recent study de-
tected CD98hc, LAT1, and MCT1 in an AHA1 interactome using







Figure 3. CRBN modulates HSP90-AHA1 activity toward client proteins
(A) IP analysis of FLAG-CRBN from HEK293T cells with co-expression of either AHA1WT or AHA1Y223E using low-salt buffer.
(B) IP analysis of FLAG-CRBNWT or CRBNYW/AA from CRBN/ HEK293T WCE in low-salt buffer. Cells were treated with DMSO or lenalidomide (50 mM) for 24 h
prior to harvest and immunoblot analysis.
(C) IP analysis of FLAG-AHA1 mutants transfected into HEK293T cells using low-salt buffer.
(D) IP analysis of FLAG-CRBN transfected into HEK293T cells, in which AHA1 was lentivirally silenced using the indicated shRNAs.
(E) Immunoblot analysis of HEK293T cells transfected with CFTR, FLAG-AHA1Y223E, and different CRBN constructs as indicated. Cells were treated with DMSO
or lenalidomide (50 mM) for 24 h prior to harvest and immunoblot analysis.
(F) Quantification of the immunoblot analysis (lanes 2–4) presented in (C) (n = 3 independent experiments).
(G) In vitro ATPase activity of HSP90 with addition of CRBN, AHA1WT purified from 293T cells. Lenalidomide (1 mM) was added as indicated. Purified proteins are
shown in Figure S4H.
Data in this figure are mean ± SD. **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-sample t test or Student’s t test.
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Figure 4. CRBNs is a transmembrane protein-specific co-chaperone of the HSP90-AHA1 axis
(A) Immunoblot analysis of TM proteins identified in the cell surface analysis (left panel) and known non-TM HSP90 clients (right panel) fromMM1S cells that were
treated with 10 mM lenalidomide or 1 mM 17-AAG for 72 h before harvest.
(B) Representative immunofluorescence images of HeLa cells that were transfected with constructs encoding HA-CD98hc and FLAG-LAT1. The cells were
stained with antibodies to HA (green) and FLAG (red). DNA was stained with DAPI (blue). Cells were treated with 50 mM lenalidomide, 50nM 17-AAG, and DMSO
for 16 h as indicated. Scale bars, 10 mm. Quantification is presented in Figures S6D and S6E.
(legend continued on next page)
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TP-specific co-chaperone of HSP90, which assures proper
client folding by counteracting AHA1. IMiDs abrogate binding
of CRBN to both HSP90 and de novo synthesized TPs, resulting
in increased AHA1 activity, insufficient client folding, and subse-
quent destabilization of TPs such as CD98hc and LAT1
(Figure 4F).
Loss of CD98hc/LAT1 quality control blocks MM cell
proliferation and perturbs cellular amino acid
metabolism
Next, we assessed the contribution of CD98hc/LAT1 destabiliza-
tion to the versatile anti-myeloma effects of IMiDs. Indeed, RNAi-
mediated knockdown of CD98hc and LAT1 markedly reduced
proliferation of both IMiD-sensitive and IMiD-resistant MM cell
lines (Figures 5A and S7A), while overexpression of CD98hc
and LAT1 increased proliferation (Figures 5B and S7B). In
contrast, lenalidomide destabilized CD98hc and LAT1 in IMiD-
sensitive cell lines such as MM1S and U266, while their levels re-
mained unaffected in naturally IMiD-resistant cell lines such as
KMS12BM and RPMI8226 (Figure 5C). Moreover, cell surface
expression of CD98hc, as measured by flow cytometry, was
significantly reduced upon lenalidomide in sensitive but not in
resistant cells (Figures 5D and 5E). Importantly, overexpression
of CD98hc or LAT1mitigated the anti-proliferative effect of IMiDs
in MM1S cells, confirming that persistence of CD98hc and LAT1
associates with resistance to IMiD treatment (Figures 5F and
S7C). These findings nominate CD98hc or LAT1 as attractive
therapeutic targets in both the IMiD-sensitive and IMiD-resistant
setting. Notably, JPH-203, a specific LAT1 inhibitor, is currently
being tested for the treatment of various malignancies (Okano
et al., 2018). In MM, we found JPH-203 to significantly reduce
cell growth of both IMiD-sensitive and IMiD-resistant cell lines
(Figure 5G). Likewise, the HSP90 inhibitor 17-AAG destabilized
CD98hc/LAT1 and substantially reduced proliferation in IMiD-
resistant cell lines (Figures 5H and S7D). The combination of
17-AAG and lenalidomide moreover showed synergistic anti-
myeloma effects in MM1S cells (Figure S7E).
Extracellular supply of amino acids such as glutamine and
leucine marks a strong dependency for MM cell growth (Bolzoni
et al., 2016). The CD98hc/LAT1 complex is a sodium-indepen-
dent exchanger of bulky aliphatic and aromatic amino acids,
including the essential amino acid L-leucine (Yan et al., 2019),
and is functionally linked to glutamine transport and amino
acid-dependent mTOR activity, two further dependencies of
MM (Eichner et al., 2019; Fernández-Sáiz et al., 2013; Nicklin
et al., 2009). We therefore testedwhether IMiDs influence the up-
take of essential amino acids. Strikingly, lenalidomide treatment
significantly reduced the uptake of 14C-labeled L-leucine in MM
cells (Figure 5I), to a similar extent as RNAi-mediated depletion of
LAT1 or specific inhibition using BCH and JPH-203 (Figures 5I,
5J, and S7F).(C) IP analysis of FLAG-CD98hc from HEK293T cells that were treated with cyclo
synthesis.
(D) IP analysis of FLAG-LAT1 from HEK293T cells that were processed and anal
(E) Immunoblot analysis of MM1S cells, in which AHA1 was lentivirally silenced u
(F) Schematic representation of CRBNs function toward TP clients in the absenc
1178 Molecular Cell 81, 1170–1186, March 18, 2021These data further distinguish CD98hc/LAT1 as an important
vulnerability in MM, whose direct inhibition or IMiD-induced
destabilization results in reduced proliferation and inhibition of
essential amino acid uptake.
IMiDs exert anti-myeloma activity via destabilization of
CD98hc and LAT1 in vivo and in primary patient samples
To assess the relevance of CD98hc/LAT1 destabilization in vivo,
we extended our investigations to MM xenograft experiments.
First, we injected human MM cells with silenced CD98hc and
LAT1 expression subcutaneously into opposing flanks of NOD-
SCID mice. In agreement with our in vitro data, depletion of
CD98hc and LAT1 led to significantly reduced tumor growth
as assessed by 18F-fluorodeoxyglucose positron emission to-
mography (18F-FDG-PET) (Figures 6A–6D). Reduced CD98hc
and LAT1 levels were ascertained via immunohistochemistry
(IHC) (Figure 6E). In addition to 18F-FDG-PET, mice also under-
went 18F-fluoroethyltyrosine PET (18F-FET-PET) (Figure 6A,
lower panel). 18F-FET is a radiolabeled amino acid analog pre-
dominantly transported by LAT1 (Habermeier et al., 2015).
Notably, we observed a significantly lower 18F-FET-PET/18F-
FDG-PET signal ratio in CD98hc/LAT1-depleted tumors, indi-
cating reduced amino acid uptake (Figure 6F). In a second
approach, unmodified IMiD-sensitive MM1S cells were injected
subcutaneously, andmicewere randomly assigned to receive le-
nalidomide or control treatment upon tumor engraftment. Lena-
lidomide treatment halted tumor progression and reduced
CD98hc and LAT1 expression as shown by IHC analyses (Fig-
ures 6G, S7G, and S7H).
Finally, CD138+ MM cells were isolated from bone marrow as-
pirates from either lenalidomide-sensitive or resistant patients
and treated with lenalidomide in vitro. In line with our observation
in MM cell lines, we found decreased CD98hc/LAT1 levels and
CD98hc cell surface expression in cells obtained from IMiD-sen-
sitive patients, while no change was noted in patients with docu-
mented lenalidomide resistance (Figures 6H, 6I; and S7I). The
close correlation of CD98hc/LAT1 destabilization with IMiD
sensitivity implies that IMiD-induced change of CD98hc/LAT1
levels could serve as a predictive marker for IMiD response.
A CD98hc-directed Anticalin (D11vs) provides a radio-
theranostic tool for MM
Anticalins constitute a clinical stage class of non-immunoglob-
ulin-binding proteins, derived from human lipocalins, that pro-
vide functional benefits such as small size, robust and compact
fold, and pronounced target specificity (Rothe and Skerra, 2018).
Recently, we developed an Anticalin on the basis of the human
lipocalin Lcn2, which specifically binds and detects the human
CD98hc ectodomain with picomolar affinity (Deuschle et al.,
2020). Indeed, when used in our MMmodel, a PASylated variant
(Schlapschy et al., 2013) of this Anticalin (Anticalin-PAS200)
coupled to the fluorophore sulfoCy5.5 (sCy5.5) specificallyheximide (CHX) for the indicated times before harvest to block de novo protein
yzed as in (C).
sing the indicated shRNAs.
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ficity was further established using the corresponding PASylated
wild-type Lcn2 (wtLcn2-PAS200) and by blocking with an excess
of unlabeled Anticalin-PAS200 (Figure 7G). Importantly, Anticalin-
PAS200 was able to detect IMiD-induced destabilization of
CD98hc in MM1S cells and also in primary CD138+ MM cells,
which were treated with lenalidomide in vitro (Figures 7H and
7I). For application in vivo, the Anticalin-PAS200 was site-specif-
ically conjugated with deferoxamine and labeled with zirconium-
89, and MM1S cells were subcutaneously injected into NOD
SCID mice. Following tumor engraftment, mice were injected
with Anticalin-PAS200-89Zr and imaged using PET/CT. Although
specific accumulation of the radio ligand was detectable in the
xenograft tumor (Figure 7J), additional intravenous (i.v.) applica-
tion of an excess amount of the unlabeled Anticalin-PAS200
blocked this accumulation (Figure 7K), thus ascertaining speci-
ficity (Figures 7J–7L).
Taken together, these findings provide a novel CD98hc-spe-
cific theranostic tool for further research and potential clinical
application in MM.
DISCUSSION
The protein CRBN has received particular attention as the pri-
mary target of IMiDs (Fischer et al., 2014; Ito et al., 2010), which
have been shown to induce the interaction between CRBN and a
set of neo-substrates including IKZF1, IKZF3, and CK1a, result-
ing in their ubiquitination and the subsequent proteasomal
degradation (Gandhi et al., 2014; Krönke et al., 2014, 2015; Lu
et al., 2014). Although the ubiquitin-dependent degradation of
neo-substrates accounts for some of the known IMiDs effects,
many open questions remained because they do not explain
the plethora of IMiD functions such as the anti-angiogenic,
anti-invasive, and also immune-modulatory effects. Most impor-
tant, however, the well-documented synergy of IMiDs with the
reversible and irreversible proteasome inhibitors bortezomib
and carfilzomib creates a paradox, as they would be predicted
to antagonize each other. Instead, this synergy suggests theFigure 5. Loss of CD98hc/LAT1 quality control blocks MM cell prolifer
(A) Cell proliferation analysis of the indicated MM cell lines, in which CD98hc or
immunoblot analysis is presented in Figure S7A.
(B) Cell proliferation analysis of MM1S cells that were lentivirally infected with e
expression. The corresponding immunoblot analysis is presented in Figure S7B.
(C) Representative immunoblot analysis of lenalidomide-sensitive (MM1S, U266)
10 mM lenalidomide or DMSO for 72 h.
(D) Representative flow cytometry analysis of endogenous CD98hc cell surfac
(KMS12BM) MM cell line treated with 10 mM lenalidomide or DMSO for 72 h.
(E) Quantification of three independent experiments presented in (D) using media
control.
(F) Cell proliferation analysis of MM1s cells, which were lentivirally infected with em
treated with DMSO or 10 mM lenalidomide for 72 h. The corresponding immunob
(G) Cell proliferation analysis of the indicated MM cell lines, which were treated w
(H) Cell proliferation analysis of the indicated IMiD-resistant MM cell lines, whic
sponding immunoblot analysis is presented in Figure S7D.
(H) Radioactive amino acid uptake analysis in MM1S cells, which were pulsed wi
BCH (1 M) and JPH-203 (1 mM) or 72 h with lenalidomide (10 mM) or DMSO prior
(I) Radioactive amino acid uptake analysis in MM1S cells performed as in (H). LA
analysis is presented in Figure S7F.
Data in this figure are expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p <
1180 Molecular Cell 81, 1170–1186, March 18, 2021presence of ubiquitin-independent mechanisms of IMiD action
(Attal et al., 2017; Stewart et al., 2015). Indeed, we previously
found CRBN to bind and stabilize the TPs CD147 and MCT1 in
a ubiquitin-independent manner and demonstrated that IMiDs
mediate anti-tumor and teratotoxic effects by interfering with
this complex (Eichner et al., 2016).
This initial observation proved to be an invaluable portal to
gain insight into the physiological functions of CRBN and even-
tually distinguish CRBN as a fundamental player in the quality
control of TPs, which is further supported by previous findings
that CRBN binds chloride and potassium channels (Higgins
et al., 2008; Hohberger and Enz, 2009; Jo et al., 2005). Indeed,
we here characterize CRBN as an HSP90 co-chaperone that in-
teracts with the ATP-bound and N-terminally closed HSP90a
dimer and attenuates the negative effect of AHA1 on TP stability.
These findings provide different new aspects of how HSP90
function and TP quality control are regulated. By investigating
a panel of TPs and non-TP HSP90 client proteins, we show
that IMiD treatment or CRBN loss specifically destabilize TPs,
whereas non-TP HSP90 clients remain unaffected, thus distin-
guishing CRBN as TP-specific HSP90 co-chaperone (Figures
4A and S5A). So far, CDC37 is the only other co-chaperone
that has been demonstrated to provide HSP90 specificity to a
distinct protein family, namely, kinases (Schopf et al., 2017;
Verba et al., 2016). Selectivity via distinct co-chaperones may
thus be a more general theme by which HSP90 clients are
determined.
Our data also provide a new level of regulation of AHA1. Faith-
ful processing of individual HSP90 clients depends on the client
HSP90 dwelling time, which is determined by AHA1’s stimulation
of ATP turnover (Koulov et al., 2010). CRBN reduces HSP90 ATP
turnover via attenuation of AHA1, an effect that is reversed by le-
nalidomide. We therefore propose that the ratio of CRBN and
AHA1 within the HSP90 complex tightly regulates HSP90
ATPase activity to provide an ideal dwelling time for TP matura-
tion and energetically stable folding. IMiDs disturb this balance
by disrupting the CRBN-HSP90 interaction, leading to an imbal-
ance in favor of AHA1. As a consequence, exceedingly rapid ATPation and perturbs cellular amino acid metabolism
LAT1 were lentivirally silenced with the indicated shRNAs. The corresponding
mpty vector (EV) constructs or constructs to induce both CD98hc and LAT1
and lenalidomide-resistant (KMS12BM, RPMI8226) MM cell lines treated with
e expression in a lenalidomide-sensitive (MM1S) and lenalidomide-resistant
n fluorescence intensity (MFI). Data are shown as relative ratios of Len/DMSO
pty vector (EV) constructs or constructs to induce CD98hc or LAT1 expression
lot analysis is presented in Figure S7C.
ith DMSO or 1 mM of the LAT1 inhibitor JPH-203 for the indicated times.
h were treated with 1 mM 17-AAG or 10 mM lenalidomide for 72 h. The corre-
th 14C-labeled L-leucine. Cells were treated for 10 min with the LAT1 inhibitors
to the analysis.
T1 was silenced using the indicated shRNAs. The corresponding immunoblot
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Figure 6. IMiDs exert anti-myeloma activity via destabilization of CD98hc and LAT1 in vivo and in primary patient samples
(A) Representative positron emission tomography (PET) image using either 18F-fluorodeoxyglucose (FDG) (upper panel) or 18F-fluoroethyltyrosine (FET) (lower
panel) of a representative NOD-SCID mouse that was injected subcutaneously with human MM1S cells that had been transduced with constructs expressing
(legend continued on next page)
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in poorly folded TP intermediates.
The broad impact of CRBN on TP quality control opens a new
perspective on IMiD function, which may eventually account for
the broad plethora of their clinical effects. Indeed, the anti-angio-
genic, anti-invasive, anti-proliferative, and immune-modulatory
but also the teratotoxic effects as well as the width of side effects
such as thrombosis or neuropathy could be explained by altered
TP expression. We acknowledge that a full picture of all relevant
TPs affected by IMiDs goes beyond the insights provided herein.
In this regard, a recent paper reported that IMiD resistance in
isogenic MM cell line pairs could not be overcome by the sole
silencing of CD147 (Zhu et al., 2019). This finding appears
conceivable in light of the fundamental impact of CRBN on
different TPs.
Among the TPs affected by IMiDs, we here focused on the
amino acid transporter complex CD98hc/LAT1, which is highly
expressed in MM and scored as the most significant overlap-
ping hit between cell surface proteome and CRBN interactome
analyses. This candidate makes sense in many ways, particu-
larly in the context of MM. Upregulation of amino acid trans-
porters is particularly relevant for MM cells, in which the pro-
duction of large amounts of monoclonal immunoglobulins is a
characteristic hallmark of the disease, necessitating enormous
amounts of amino acids. This particular dependency may thus
explain why IMiDs exert their highest efficacy in this disease.
The impact of IMiDs on amino acid uptake is well documented
by our in vitro uptake assays (Figures 5I and 5J) and in vivo ex-
periments using FET-PET (Figures 6A and 6F). Moreover, amino
acid deprivation and proteasomal inhibition both reduce the
pool of amino acids available for synthesis of proteins and
may thus serve as a mechanistic rationale of why IMiDs and
PIs act highly synergistically in MM. Along this line, the IMiD-
induced accumulation of misfolded TPs would also be consid-
ered synergistic with proteasomal inhibition in terms of anti-
myeloma efficacy.
Different therapeutic implications can be derived from the in-
sights described herein. So far, HSP90 inhibitors have failed in
clinical application because of toxicity, which can be well ex-
plained by the large number of HSP90 clients. Therefore, a
more selective targeting of HSP90-co-chaperone complexes
would be desirable. IMiDs could represent such molecules as
they disrupt the CRBN-HSP90a interplay to destabilize a
limited number of TPs. At the same time, specific targeting ofboth CD98hc- and LAT1-specific shRNAs (1) or control shRNA (shCtrl) (2) before
pointing to xenograft tumors. Color scale indicates percentage of injected dose
(B) Quantification of metabolic tumor volume as determined by FDG uptake (n =
(C and D) Metric quantification of tumors obtained after necropsy (n = 5 tumors
(E) Representative immunohistochemistry (IHC) analysis of tumors described in
bars, 20 mm.
(F) Comparison of metabolic volumes obtained from 18F-FET-PET images versus
(G) Representative immunohistochemistry (IHC) analysis of tumors derived from m
performed on ten high-power fields for each stain. Scale bars, 20 mm.
(H) Immunoblot analysis of primary CD138+ cells obtained from patients diagnos
MM that were cultured in vitro with DMSO or 10 mM lenalidomide for 48 h.
(I) Flow cytometry analysis of endogenousCD98hc cell surface expression of prim
(Len/DMSO) of median fluorescence intensity (MFI).
Data in this figure are expressed as mean ± SD. n.s., not significant; *p < 0.05 an
1182 Molecular Cell 81, 1170–1186, March 18, 2021the CRBN-AHA1 interaction could be a complementary
approach (Stiegler et al., 2017). Actionable therapeutic implica-
tions can also be deduced from the identification of CD98hc/
LAT1 as novel IMiD targets and meaningful vulnerabilities in
MM. We show that refractoriness to IMiD treatment consis-
tently associates with the persistence of CD98hc/LAT1expres-
sion in MM cells, while knockdown of CD98hc/LAT1 in such
cells induces their death. Targeting CD98hc/LAT1 thus appears
to be a highly attractive therapeutic approach in IMiD-refractory
patients or patients with cancers, where CD98hc/LAT overex-
pression has been observed. Indeed, treatment of IMiD-resis-
tant MM cells with JPH-203, a specific LAT1 inhibitor, reduced
cell proliferation to a similar extent as in IMiD-sensitive cells
(Figure 5G), thus warranting further development of such
agents. At the same time, early analysis of CD98hc/LAT1
expression may serve as a biomarker to predict IMiD sensitivity
in MM patients.
Finally, we show that a CD98hc-directed Anticalin is highly
enriched in xenogeneic MM tumors when linked to the diag-
nostic isotope 89Zr and imaged using PET. This tool can be
further therapeutically exploited in the context of a radio-thera-
nostic approach when linked to a therapeutic isotope such as
177Lu. This additional therapy option for IMiD-refractory pa-
tients appears promising, as they exhibit persistent high
expression of the target and are highly sensitive to ionizing ra-
diation (Mesguich et al., 2016). Future studies will elucidate
whether such an approach represents a successful treatment
modality in patients with relapsed/refractory MM and high
expression of CD98hc.
Limitations
Our data provide clear evidence for a highly specific co-chap-
erone function of CRBN toward TPs. However, our study did
not reveal a distinct recognition motif or binding site speci-
ficity in TPs by which selective binding to CRBN is procured.
Such insights may be revealed by structural studies of CRBN
bound to TPs such as CD98hc and LAT in the presence and
absence of IMiDs. These additional mechanistic details will
be subject of further investigations. The present findings
also open the field of inhibiting protein family-specific frac-
tions of HSP90 activity, as broad inhibition of HSP90 by
currently available inhibitors have failed in most clinical appli-
cations because of significant toxicity. The present study fo-
cuses on IMiDs as subset-specific HSP90 modulators, butgrafting. Images were taken 21 and 28 days after injection, with white arrows
per gram (% ID/g).
4 tumors per condition).
per condition).
(A). Analysis was performed on ten high-power fields for each stain. Scale
18F-FDG-PET images in mice described in (A).
ice that were treated with either vehicle control or lenalidomide. Analysis was
ed with lenalidomide-sensitive (Len. sens.) or lenalidomide-resistant (Len. res.)
ary CD138+ cells that were treated as in (H). Data are presented as relative ratios
d **p < 0.01 by Student’s t test (B–D and F) and one-sample t test (I).
A B C D
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chaperone interactions, other client-specific inhibitors, and
modulators of subcellular localization.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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offered by nuclear medicine for the imaging and therapy of multiple myeloma.
Theranostics 6, 287–290.
Meyer, P., Prodromou, C., Liao, C., Hu, B., Mark Roe, S., Vaughan, C.K.,
Vlasic, I., Panaretou, B., Piper, P.W., and Pearl, L.H. (2004). Structural basis
for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machin-
ery. EMBO J. 23, 511–519.
Neckers, L. (2003). Development of small molecule Hsp90 inhibitors: utilizing
both forward and reverse chemical genomics for drug identification. Curr.
Med. Chem. 10, 733–739.Molecular Cell 81, 1170–1186, March 18, 2021 1185
ll
OPEN ACCESS ArticleNicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B.,
Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009). Bidirectional transport
of amino acids regulates mTOR and autophagy. Cell 136, 521–534.
Okano, N., Kawai, K., Yamauchi, Y., Kobayashi, T., Naruge, D., Nagashima, F.,
Endou, H., and Furuse, J. (2018). First-in-human phaseIstudy of JPH203 in pa-
tients with advanced solid tumors. J. Clin. Oncol. 36, 419–419.
Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J.K., Singh, S.,
Millson, S.H., Clarke, P.A., Naaby-Hansen, S., Stein, R., et al. (2002).
Activation of the ATPase activity of hsp90 by the stress-regulated cochaper-
one aha1. Mol. Cell 10, 1307–1318.
Raza, S., Safyan, R.A., and Lentzsch, S. (2017). Immunomodulatory drugs
(IMiDs) in multiple myeloma. Curr. Cancer Drug Targets 17, 846–857.
Retzlaff, M., Hagn, F., Mitschke, L., Hessling, M., Gugel, F., Kessler, H.,
Richter, K., and Buchner, J. (2010). Asymmetric activation of the hsp90 dimer
by its cochaperone aha1. Mol. Cell 37, 344–354.
Rothe, C., and Skerra, A. (2018). Anticalin proteins as therapeutic agents in
human diseases. BioDrugs 32, 233–243.
Schlapschy, M., Binder, U., Börger, C., Theobald, I., Wachinger, K., Kisling, S.,
Haller, D., and Skerra, A. (2013). PASylation: a biological alternative to
PEGylation for extending the plasma half-life of pharmaceutically active pro-
teins. Protein Eng. Des. Sel. 26, 489–501.
Schopf, F.H., Biebl, M.M., and Buchner, J. (2017). The HSP90 chaperone ma-
chinery. Nat. Rev. Mol. Cell Biol. 18, 345–360.
Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M.K., Hartl,
F.U., and Wanker, E.E. (2001). Geldanamycin activates a heat shock response
and inhibits huntingtin aggregation in a cell culture model of Huntington’s dis-
ease. Hum. Mol. Genet. 10, 1307–1315.
Smith, C.K., Baker, T.A., and Sauer, R.T. (1999). Lon and Clp family proteases
and chaperones share homologous substrate-recognition domains. Proc.
Natl. Acad. Sci. U S A 96, 6678–6682.
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol,
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RRID:AB_2198052
Rabbit polyclonal anti-p53 Cell Signaling Technology Cat.#: 9282
RRID:AB_331476
Rabbit monoclonal anti-BCL6 Cell Signaling Technology Cat.#: 5650S
RRID:AB_10949970
Rabbit monoclonal anti-GLUT1 Cell Signaling Technology Cat.#: 12939S
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Rabbit monoclonal anti-ASCT2 Cell Signaling Technology Cat.#: 8057S
Rabbit polyclonal anti-AHA1 Abcam Cat.#: ab83036
RRID:AB_2223967
Rabbit polyclonal anti-HA Y-11 Santa Cruz Biotechnology Cat.#: sc-805
RRID:AB_631618
Rabbit polyclonal anti-MCT4 Santa Cruz Biotechnology Cat.#: sc-50329
RRID:AB_2189333
Rabbit monoclonal anti-SLC7A5/LAT1 Abcam Cat.#: ab208776
RRID: N/A
Rabbit polyclonal anti-CD38 Abcam Cat.#: ab125038
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Rabbit polyclonal anti-TEL2 Proteintech Cat.#: 15975-1-AP
RRID:AB_2203337
Rabbit polyclonal anti-HAX1 Proteintech Cat.#: 11266-1-AP
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N/A
Individually generated Rabbit polyclonal
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Protein-A-HRP GE Healthcare Cat.#: NA9120V
RRID: N/A
Anti-goat IgG-HRP Santa Cruz Biotechnology Cat.#: sc-2354
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Anti-rabbit IgG-Alexa Fluor 488 (IF) Invitrogen Cat.#: A11008
RRID:AB_143165
Anti-mouse IgG-Alexa Fluor 594 (IF) Invitrogen Cat.#: A11005
RRID:AB_2534073
Anti-sheep IgG-Alexa Fluor 633 (IF) Invitrogen Cat.#: A21100
Alexa Fluor-546-conjugated Streptavidin (IF) Invitrogen Cat.#: S11225
Sheep polyclonal Anti-TGN46 (IF) BioRad Cat.#: AHP500GT
Mouse monoclonal Biotin-conjugated
anti-Calnexin AF18 (IF)
Novus Biologicals Cat.#: NB300-518B
Anti-CD98hc-PE, clone UM7F8 (FACS) BD PharMingen Cat.#: 556077
RRID:AB_396344
Anti-Isotype control mIgG1k- PE, clone
MOPC-21 (FACS)
BD PharMingen Cat.#: 559320
RRID:AB_397218
Anti-CD98hc-APC (FACS) Miltenyi Cat.#: 130-105-662
RRID:AB_2659685
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Anti-CD138-biotin (FACS) Miltenyi Cat.#: 130-099-162
RRID:AB_2655045
Anti-CD38-biotin (FACS) Miltenyi Cat.#: 130-092-288
RRID:AB_871667
Streptavidin- eFluor450 (FACS) eBioscience Cat.#: 48431782
RRID:AB_10359737
APC Annexin V (FACS) BD PharMingen Cat.#: 550474
RRID: N/A
Bacterial and virus strains
E. Coli BL21 NEB Cat.#: C2530H
Biological samples
Mononuclear cells from bone marrow aspirates
from lenalidomide-sensitive and –refractory
MM patients
Isolated from patients N/A
Chemicals, peptides, and recombinant proteins
Lenalidomide Sigma Cat.#: SML2283
Pomalidomide Selleckchem Cat.#: S1567
Thalidomide Tocris Cat.#: 0652
BCH Sigma Cat.#: A7902
JPH-203 Tocris Cat.#: 5026
17-aag Selleckchem Cat.#: S1141
Geldanamycin AdooQ Bioscience Cat.#: A11025
Ganetespib AdooQ Bioscience Cat.#: A11402
HSP990 AdooQ Bioscience Cat.#: A12850
SNX-2112 AdooQ Bioscience Cat.#: A11189
PU-H71 AdooQ Bioscience Cat.#: A11130
Biocoll Separating Solution Biochrom Cat.#: L 6115
CD138+ micro beads MACS,
MiltenyiBiotech
Cat.#: 130-051-301
Sodium molybdate Sigma Cat.#: 331058-M
FLAG-M2 agarose beads Sigma Cat.#: A2220
HA-7 agarose beads Sigma Cat.#: A2095
Lipofectamine 2000 Thermo Fischer Cat.#: 11668019
ViaFect transfection reagent Promega Cat.#: E4981
Polybrene Sigma Cat.#: TR-1003
Isopropyl-b-D-thiogalactopyranoside (IPTG) Sigma Cat.#: I6758
Glutathione Sepharose 4B beads Amersham Biosciences Cat.#: 17075601
rProtein A Sepharose Fast Flow Merck/GE Healthcare Cat.#: 17-1279-01
Gold Antifade Mountant Invitrogen Cat.#: P36930
14C-L-Leucine Moravek Inc. Cat.#: MC175
Ultima Gold XR scintillation cocktail Perkin Elmer Cat.#: 6013119
Strep-Tactin Superflow Sepharose IBA Lifesciences Cat.#: 2-1208-002
Amicon Ultra-0.5 mL 10k Centrifugal Filters Merck Millipore Cat.#: UFC501008
Critical commercial assays
TNT T7 quick-coupled transcription/translation system Promega Cat.#: L1171
Molecular Probes PiPer Phosphat-Assay-Kit Thermo Fisher Cat.#: P22061
RNeasy Kit QIAGEN Cat.#: 74104
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Deposited data
Mass spectrometric data PRIDE database PXD018244
Experimental models: cell lines
HEK293T ATCC Cat.#: CRL-3216
RRID:CVCL_0063
CRBN/ HEK293FT Laboratory of WG Kaelin N/A
HeLa ATCC Cat.#: CCL-2
RRID:CVCL_0030
Human: MM1.S ATCC Cat#CRL-2974
RRID:CVCL_8792
Human: MM1.S CRBN/ clones T11 and T21 Laboratory of WG Kaelin N/A
Human: U266B1 DSMZ Cat.#: ACC-9
RRID:CVCL_0566
Human: KMS 12BM DSMZ Cat.#: ACC-551
RRID:CVCL_1334
Human: RPMI 8226 DSMZ Cat.#: ACC-402
RRID:CVCL_0014
Human: JJN3 DSMZ Cat.#: ACC-541
RRID:CVCL_2078
Experimental models: organisms/strains
Mice: NOD.CB17/AlhnRj-Prkdcscid/Rj Janvier/Charles River N/A
Oligonucleotides
shRNA CRBN: (#1) 50-CGCTGGCTGTATTCCTTATAT-30
and (#2) 50- CCAGAAACATCTACTTGGGTA 30
Krönke et al., 2014 N/A
shRNA CD98hc (#1) 50- AGTCTCTTGCAATCGGCTAAA
30 and (#2) 50- GCCTACTCGAATCCAACAAAG 30
This paper N/A
shRNA LAT1 (#1) 50- CTAGATCCCAACTTCTCATTT
30 and (#2) 50- GAACATTGTGCTGGCATTATA 30
This paper N/A
shRNA AHA1 (#1) 50- CAATCGCAAAGGGAAACTTAT





mRNA primer: LAT1: 50- GAAGAGGCGCGGGAGAAG
AT-30 and and 50- GTTGAGCAGCGTGATGTT CC-30
This paper N/A
mRNA primer: CD98hc: 50- ATGGAGCTACAGCCTCC
TGA-30 and 50- CGCGCTGAGACCCTGG 30
This paper N/A




pcDNA Human CRBN Source Bioscience N/A
pcDNA CD98hc Source Bioscience N/A
pcDNA LAT1 Source Bioscience N/A
pcDNA HSP90A/B Source Bioscience N/A
pcDNA AHA1 Source Bioscience N/A
pcDNA ASCT2 Source Bioscience N/A
pcDNA CFTR Raymond A. Frizzell N/A
pcDNA HA Life technologies N/A
pcDNA Flag Life technologies N/A
pHIV-EGFP Addgene Cat.#: 21373
RRID:Addgene_21373
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pLKO.1 TRC Addgene Cat.#: 10878
RRID:Addgene_10878
Scramble shRNA Addgene Cat.#: 1864
RRID:Addgene 1864
pMD2.G Addgene Cat.#: 12259
RRID:Addgene_12259
psPAX2 Addgene Cat.#: 12260
RRID:Addgene_12260
pDONR221 GLUT1 Addgene Cat.#: 132103
RRID:Addgene_132103
pDONR221 NHE1 Addgene Cat.#: 132246
RRID:Addgene_132246
pDONR221 MCT4 Addgene Cat.#: 131899
RRID:Addgene_131899
pcDNA3-HA2 CaUL4A Addgene Cat.#: 19907
RRID:Addgene_19907
pcDNA3-Flag DDB1 Addgene Cat.#: 19918
RRID:Addgene_19918
pcDNA3-FBXL6-Flag Addgene Cat.#: 19904
RRID:Addgene_19904
pLPC-MYC hTel2 Addgene Cat.#: 22802
RRID:Addgene_22802
pcDNA3.1/C-(K)DYK WT1 GenScript Cat.#: OHu27351
pGEX-4T2 GE Healthcare 28-9545-50









FlowJo software FlowJo https://www.flowjo.com/solutions/flowjo/
downloads
RRID:SCR_008520




MaxQuant (v1.6.0.16) MaxQuant https://www.maxquant.org
Inveon Research Workplace software Siemens medical solutions N/A
Data availability





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Florian
Bassermann (florian.bassermann@tum.de).
Materials availability
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The mass spectrometry proteomics raw data (cell surface proteome screen and CRBN interactome) have been deposited on the
PRIDE server (https://www.ebi.ac.uk/pride/archive/) with the following accession number: PXD018244.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and drug treatments
HEK293T (ATCC: CRL-3216), CRBN/HEK293FT (kindly provided byWGKaelin) and HeLa (ATCC: CCL-2) cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-strepto-
mycin. The human multiple myeloma cell lines MM1.S (ATCC: CRL-2974), MM1.S CRBN/ (independent clones T11 and T21;
both kind gifts of WG Kaelin), U266 (DSMZ: ACC-9), KMS 12BM (DSMZ: ACC-551), RPMI 8226 (DSMZ: ACC-402), JJN3 (DSMZ:
ACC-541) were cultured in RPMI-1640 (GIBCO) with 10% heat-inactivated FBS and 1% penicillin-streptomycin. All cells tested my-
coplasma negative by a PCR detection method.
Primary multiple myeloma cells
The study of MM cells derived from patients treated in our hospital was in accordance with the ethical standards of the institutional
and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
The investigation was approved by the Local Ethics Committee of our University Hospital (ethical approval # 438/19 S). Written
informed consent was obtained from each patient.
Studies in mice
For CD98hc/LAT1 knockdown studies, female NOD.CB17/AlhnRj-Prkdcscid/Rj mice 8–10weeks of age (Janvier) were used. For Anti-
calin xenograft experiments female NODSCIDmice 8-10 weeks of age (Charles River) were used. Mice were housed under SPF con-
dition and animal experiments were conducted with permission from the District Government of Upper Bavaria (application no.:
55.2-2532.Vet_02-16-141 / 55.2-1-54-2532-216-15).
METHOD DETAILS
Cell culture drug treatment
Where indicated, lenalidomide (Sigma), pomalidomide (Selleckchem), thalidomide (Tocris), BCH (Sigma), JPH-203 (Tocris), 17-AAG
(Selleckchem), Geldanamycin, Ganetespib, HSP990, SNX-4112, PU-H71 (all AdooQ Bioscience) were used at the indicated
concentrations.
Isolation of CD138+ primary MM cells
Mononuclear cells from bone marrow aspirates from lenalidomide-sensitive and –refractory MM patients were isolated using Biocoll
Separating Solution (Biochrom) and enriched for CD138+ cells by magnetic bead selection (MACS, MiltenyiBiotech) according to the
manufacturer’s instructions. CD138+ cells were taken into culture in IMDM (GIBCO) with 20% heat-inactivated FBS and 1% peni-
cillin-streptomycin for 48 hours in presence of 10mM lenalidomide or vehicle (DMSO) and subsequently analyzed by flow cytometry,
and, where possible, harvested for immunoblot analysis.
Plasmids and shRNAs
Human CRBN, CD98hc, LAT1, ASCT2, HSP90⍺, HSP90B, AHA1 cDNA was purchased from Source Bioscience. Human GLUT1,
NHE1,MCT4, CUL4A, DDB1, FBXL6, TEL2 cDNAwas purchased fromAddgene. HumanWT1 cDNAwas purchased fromGenScript.
A human HAX1 construct was kindly provided by J. Ihle. A human CFTR construct was kindly provided by Raymond A. Frizzell. Point
mutants of CRBN, HSP90⍺ and AHA1 were generated using site-directed mutagenesis. cDNAs of CRBN CD98hc, LAT1, HSP90⍺,
HSP90B, AHA1, CFTR were cloned without tag or with HA- or FLAG-tag into the expression plasmid pcDNA3.1 (Life technologies).
FLAG-tagged fragments of CRBN (Sequences specified in Figure S3E) were subcloned into the expression plasmid pcDNA3.1 (Life
technologies). cDNAs of CD98hc and LAT1 were cloned into the pHIV-EGFP plasmid (Addgene) or a pHIV-EGFP variant where the
EGFP sequence was replaced by the cDNA coding for DsRed-Express2. Full-length CRBN and fragments of CD98hc (isoform 1 AA
1-184, isoform 3 AA 1-122), LAT1 (N-terminal AA 1-49, middle AA 340-395, C-terminal AA 479-507) and HSP90 (N-terminal AA 9-236,
middle AA 272-617, C-terminal AA 626-732) were cloned into the pGEX-4T2 expression vector. All cDNAs were sequenced. For
shRNA mediated silencing of CRBN, CD98hc, LAT1, AHA1, specific shRNAs were cloned into the pLKO.1 TRC plasmid (Addgene),
where the puromycin resistance cassette was replaced by the cDNA coding for DsRed-Express2. sh_scramble (Addgene) was used
as control. The shRNA target sequences for CRBN were: (#1) 50-CGCTGGCTGTATTCCTTATAT-30 and (#2) 50- CCAGAAACATCT
ACTTGGGTA30 (derived from (Krönke et al., 2014)), for CD98hcwere (#1) 50- AGTCTCTTGCAATCGGCTAAA30 and (#2) 50- GCCT
ACTCGAATCCAACAAAG30, for LAT1 were (#1) 50- CTAGATCCCAACTTCTCATTT 30 and (#2) 50- GAACATTGTGCTGGCATTATA
30, for AHA1 were (#1) 50- CAATCGCAAAGGGAAACTTAT30 and (#2) TACTACTTTGAGGGCATTAAA30, forCTRL / sh_scramble
were: 50- CCTAAGGTTAAGTCGCCCTCG 30.e6 Molecular Cell 81, 1170–1186.e1–e10, March 18, 2021
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Antibodies
Mouse monoclonal antibodies were purchased from Invitrogen (CUL1-2H4C9: #32-2400), Sigma (FLAG-M2: #F3165, b-actin:
#A-1978), Enzo (p23: ADI-SPA-670D, HOP: ADI-SRA-1500D, HSP90b: #ADI-SPA843-D), Covance (HA-16B12: #MMS-101P), Cell
Signaling (CHK1: 2360S) and Santa Cruz (CD147 8D6: #sc-21746, CD98hc: sc-376815, NHE1: #sc-136239, ENT1: sc-377283,
CD44: sc-7297). Rabbit polyclonal antibodies were from Millipore (MCT1: #AB-3538P, CFTR: M3A7#), Sigma (FLAG: #F7425),
Cell Signaling (IKZF1: #5443, IKZF3: #12720, HSP90: #4877S, LAT1: #5347S, GR: #12041T, CHIP: #2080S, BCL6: #5650S,
GLUT1: #12939S, ASCT2: #8057S,), Abcam (AHA1 ab83036), Bethyl Laboratories (CUL4A: # A300-739A, RAPTOR: #A300-553A),
Enzo (HSP90a: #ADI-SPS-771F), Proteintech (TEL2: #15975-1-AP, HAX1: #11266-1-AP, WT1: #12609-1-AP, CUL4B: #12916-1-
AP) and Santa Cruz (HA Y-11: #sc-805, MCT4: #sc-50329). A rabbit polyclonal anti-FBXO9 antibody was a kind gift of Michele Pa-
gano. A polyclonal antibody against CRBN was generated by immunizing rabbits with a mixture of two peptides containing amino
acids 1-19 and 424-437 of human CRBN (MAGEDQQDAAHNMGNHLPC and CPTIDPTEDEISPDK) with Innovagen. Secondary an-
tibodies (anti-rabbit IgG, anti-mouse IgG or protein-A) coupled with horseradish peroxidase were from GE Healthcare, an anti-goat
IgG secondary antibody was from Santa Cruz. Secondary antibodies (anti-rabbit IgG and anti-mouse IgG) coupled to Alexa Fluor 594
or Alexa Fluor 488 for immunofluorescence and flow cytometry were from Life technologies.
Cell lysis, immunoprecipitations and immunoblotting
Cell samples were lysed in standard lysis buffer (NaCl 150mM, Tris-HCl 50mM pH 7.5, MgCl2 5mM, EDTA 1mM, NP-40 0.1%, Glyc-
erol 5% and protease inhibitors) unless otherwise specified. 20mM sodium molybdate (Sigma) was added where indicated. Some
experiments were conducted under low salt conditions (NaCl 20mM, Tris-HCl 50mM pH 7.5, EDTA 1mM, NP-40 0.1%, MgCl2
5mM, glycerol 5%) as indicated in the figure legends. Extract preparation, immunoprecipitation, and immunoblotting have been pre-
viously described (Bassermann et al., 2008; Baumann et al., 2014; Fernández-Sáiz et al., 2013). The cellular lysates were centrifuged
15 min at 14 000 rpm at 4C to separate from cellular debris, protein concentration was measured using a Bio-Rad DC protein assay
(Lowry assay) and Laemmli buffer was added. The lysates were separated by SDS-PAGE and blotted onto PVDF membranes (Milli-
pore). Equal protein levels were confirmed by Ponceau S staining. After blocking unspecific binding in 5% milk, membranes were
incubated with primary antibodies diluted in 5% milk or 5% BSA (bovine serum albumin). After addition of horseradish peroxidase
coupled secondary antibodies, western blot membranes were developed using the ECL (enhanced chemo luminescence) method
(SuperSignal West, Thermo Scientific). Densitometric quantification of bands was performed using Quantity One software (Biorad)
on low saturation exposures. For immunoprecipitations (IPs), cell lysates were incubated with FLAG-M2 agarose beads (Sigma) for
FLAG-IPs and HA-7 agarose beads (Sigma) for HA-IPs. For endogenous IPs, WCEwere subjected to a pre-clear with Prot. A Sephar-
ose (Merck) for 1h at 4C and followed by an overnight incubation with 8mg a-CRBN or a-IgG rabbit (Bethyl) antibody. The next day
Prot. A Agarosewas added after blocking in 5%BSA for 30minutes at 4C. After washing the beads four times in lysis buffer, Laemmli
buffer was added and proteins were analyzed by SDS-electrophoresis.
Transient transfections and lentivirus-mediated DNA transfer
HEK293T cells were transfected using the calcium phosphate method, HeLa cells were transfected with Lipofectamine transfection
reagent (Invitrogen) or ViaFect transfection reagent (Promega) according to themanufacturer’s instructions. For lentivirus production,
HEK293T cells were transfected with shRNA encoding pLKO.1 plasmids (Addgene) or, for overexpression, pHIV-EGFP (Addgene)
based constructs, together with the envelope plasmid pMD2.G (Addgene) and the packaging plasmid psPAX2 (Addgene). 48 hours
after transfection, the virus-containing medium was collected and supplemented with 8mg/ml Polybrene (Sigma).
For infection, MM cell lines or HeLa cells were plated in 6 well plates and incubated with the virus-containing supernatant for
24 hours. Cells were spin infected at 1000 rpm for 30 min at 37C. Cell lines with low infection rates were subsequently sorted for
positive cells using FACSAria (BD Biosciences).
Recombinant proteins and GST- affinity purifications
GST fusion proteins were purified from E. Coli BL21 cells after induction with isopropyl-b-D-thiogalactopyranoside (IPTG) in NETN
buffer (NaCl 100mM, Tris-HCl 20mM pH 7.5, EDTA 1mM, NP-40 0.5%, PMSF 2mM and protease inhibitors). For GST affinity puri-
fications, pre-cleared mammalian cell lysates were incubated with empty glutathione Sepharose 4B beads (Amersham Biosciences)
or GST- purified proteins for 1.5 hours. For IVT assays, purified GST-Fragments of CD98hc and LAT1 were incubated with in vitro-
translated CRBN in binding buffer (13 phosphate-buffered saline [PBS], 0.1%NP-40, 0.5mMdithiothreitol [DTT], 10%glycerol, sup-
plemented with protease inhibitors). In vitro translation was done with the TNT T7 quick-coupled transcription/translation system
(Promega Corporation, Madison, Wis.) following the manufacturer’s instructions.
Indirect immunofluorescence
Immunofluorescence was performed as previously described (Eichner et al., 2016) . Briefly, wild-type HeLa cells, or HeLa cells ex-
pressing shCRBN or shCtrl, were plated on chambered PCA tissue-culture slides (Sarstedt) and transfectedwith constructs express-
ing FLAG-LAT1 and HA-CD98 by using Lipofectamine (Invitrogen). Where indicated, cells were treated with 50 mM lenalidomide for
72 h or 50 nM 17-AAG for 16 h or DMSO as a control. For immunofluorescence, cells were washed in PBS, fixed and permeabilized in
100%methanol at 20C for 10 min, and then incubated with the primary antibodies anti-FLAG rabbit (Merck), anti-HA mouse (Bio-Molecular Cell 81, 1170–1186.e1–e10, March 18, 2021 e7
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20 in PBS (0.5% TBST). Slides were washed three times in 0.5% TBST for 5 min and incubated with the secondary antibodies Alexa
Fluor-488-, Alexa Fluor-594-, or Alexa Fluor-633-conjugated anti-rabbit, anti-mouse, and anti-sheep antibodies (Invitrogen), or Alexa
Fluor-546-conjugated Streptavidin, diluted 1:1,000 in 0.5% TBST. Slides were washed three times and subsequently mounted with
Gold Antifade Mountant (Invitrogen) containing DAPI for counterstaining of nuclei. Images were acquired with a Leica TCS SP8 WLL
confocal microscope.
mRNA analysis
For quantification of CD98hc, LAT1 and ARPP P0mRNA expression in human cell lines, total RNA was extracted using the RNeasy
Kit (QIAGEN). cDNA synthesis was performed using Superscript III (Life technologies). Quantitative PCR analysis (SYBR Green) was
performed on the LC480 instrument (Roche) according to standard procedures. ARPP (acidic ribosomal phosphoprotein P0) was
used as internal reference. Primer sequences were as follows:
LAT1: 50- GAAGAGGCGCGGGAGAAG AT-30 and 50- GTTGAGCAGCGTGATGTT CC-30; CD98hc: 50- ATGGAGCTACAGCCTC
CTGA-30 and 50- CGCGCTGAGACCCTGG 30; ARPP: 50-GCACTGGAAGTCCAACTACTTC-30 and 50-TGAGGTCCTCCTTGGTG
AACAC-30.Flow cytometry
MM cell lines
MM1.S cells treated with lenalidomide or DMSO for 72 hours were incubated with CD98hc-PE (BD PharMingen, clone UM7F8) or its
Isotype control mIgG1k- PE (BD PharMingen, clone MOPC-21) or CD98hc-APC (Miltenyi 130-105-662) or its Isotype control REA
Control APC (Miltenyi 130-104-615). After washing, stained cells were analyzed for CD98hc expression using a FACSCalibur (Becton
Dickinson) or BD FACSCanto (BD Biosciences) and data were analyzed using FlowJo software (TreeStar Inc.).
Primary MM cells
Cells were collected and washed with PBS. Subsequently, cells were stained with CD138-biotin (Miltenyi, cat.: 130099162) and
CD38-biotin (Miltenyi, cat.: 130092288) antibodies, followed by incubation with Streptavidin- eFlour450 (PB) (eBioscience, cat.:
48431782) and CD98hc-PE (BD PharMingen, clone UM7F8) or its Isotype control mIgG1k- PE (BD PharMingen, clone MOPC-21)
antibodies. The combination of APCAnnexin V (BD PharMingen) and PI was added to each sample for the determination of apoptosis
and necrosis. Flow cytometry was performed on a CyAn ADP LxP8 (Coulter-Cytomation) and data were analyzed using FlowJo soft-
ware (TreeStar Inc.). Median fluorescence intensity was calculated on CD98hc-PE and its respective isotype control mIgG1k- PE. All
human specimens were processed with informed consent in compliance with the institutional review board at the Faculty ofMedicine
of the Technical University of Munich.
Anticalin flow cytometry
Cells were resuspended in 250 mL FACS buffer (PBS + 10% (v/v) FBS) supplemented with 1 mMD11vs-PAS200-Cy5.5 and incubated
for 1h at 4C. Competition experiments were performed by adding a 100-fold molar concentration of the soluble hCD98hcED. The
Sulfo-Cy5.5 conjugate of recombinant wtLcn2-PAS200 was used as a negative. After washing, stained cells were analyzed for
CD98hc expression using a FACSCalibur (Becton Dickinson) or BD FACSCanto (BD Biosciences) and data were analyzed using
FlowJo software (TreeStar Inc.).
Cell Proliferation
MMcells were subjected to treatment with various drugs for the indicated times or infected with lentiviral-shRNA. On days indicated,
proliferation was assessed using the trypan blue exclusionmethod. Results are presented as ratios to vehicle, wild-type or sh_scram-
ble controls.
L-Leucine transport assay
For L-Leucine import studies MM1S (wt or sh scr/sh LAT1) cells were pre-treated with 10 mM lenalidomide or DMSO for 72hrs. Fresh
lenalidomide was added after 48h. 13 106 Cells were harvested on day 3 and washed 3x in preheated sodium-free Hanks Balanced
Salt Solution (HBSS: 125mM choline chloride, 4.8mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 1.3mM CaCl2, 5.6 mM glucose, 25mM
HEPES). Cells were incubated in HBSS with 1 mM JPH-203 (Sigma), 1mMBCH (Sigma) or vehicle control for 10min at 37C, followed
by a 1-minute incubation with 1 mM 14C-L-Leucine (MC175, Moravek Inc.) at 37C. Cells were washed 3x with ice-cold HBSS (sup-
plemented with 1 mM non-labeled L-Leucine) and lysed in 50 mL lysis buffer followed by a 15-minute incubation on ice. For the mea-
surement the lysate was mixed with 1ml Ultima Gold XR scintillation cocktail (Perkin Elmer) and measured on a b-liquid scintillation
counter (TRI-CARB4910TR, Perkin Elmer).
ATPase assays
AHA1-FLAG, HA-HSP90 and CRBN-Strep-Strep-FLAG were transiently expressed in HEK293T cells as described above. Proteins
were immunoprecipitated using FLAG-, HA-agarose (both Sigma) or Streptactin Superflow Sepharose (IBA Lifesciences) respectivelye8 Molecular Cell 81, 1170–1186.e1–e10, March 18, 2021
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TrisHCl pH 7.5). Proteins were then eluted using the corresponding FLAG/HA peptides or Desthiobiotin containing Buffer E. Proteins
were concentrated and separated frompeptides using AmiconUltra-0.5mL10kCentrifugal Filters (MerckMillipore). Proteinswere visu-
alized by SDS-PAGE andCoomassie Brilliant Blue staining. The ATPase activity of humanHSP90was thenmeasured using the purified
proteins in the Molecular Probes PiPer Phosphate-Assay-Kit (Thermo Fisher) according to the manufacturer’s instructions.
Studies in mice
For knock-down xenograft experiments, MM1S cells were lentivirally infected with either shRNA constructs specifically targeting
CD98hc and LAT1 or scrambled control shRNA. From both derived MM1S transduction-lines 0.6 3 107 cells were suspended in
PBS, mixed with Matrigel Basement Membrane Matrix (BD Bioscience) at a 1:1 ratio and injected subcutaneously into the opposite
flanks of randomly selected female NOD.CB17/AlhnRj-Prkdcscid/Rj mice 8–10 weeks of age (Janvier). For Anticalin xenograft exper-
iments, 0.6 3 107 wild-type MM1S cells were injected together with Matrigel s.c. into the right flank of female NOD SCID mice
8-10 weeks of age (Charles River). Mice were housed under SPF condition and animal experiments were conducted with permission
from the District Government of Upper Bavaria (application no.: 55.2-2532.Vet_02-16-141 / 55.2-1-54-2532-216-15)
Imaging and ex vivo analyses
Three to four weeks post xenograft implantation, all mice underwent imaging using an Inveon micro-PET/CT small animal scanner
(Siemens Preclinical Solutions). For the knock-down study, a dose of 5-10 MBq 18F-FDG was administered by tail vein injection
and a 15-min static image was acquired 45 min post injectionem. For the Anticalin study mice were injected with 5.0 ± 0.4 MBq
of 89Zr-PAS(200)-D11vs that had be produced, conjugated and radiolabeled as described before (Deuschle et al., 2020) and static
PET-images of 30 min were recorded 24 h post injectionem. The cohort in which the binding of the 89Zr-Anticalin was blocked
competitively received an additional 1000-fold molar excess of the ‘cold’ PASylated Anticalin. Imaging data from both studies
was reconstructed using the OSEM-3D algorithm and data analysis was performed using the Inveon Research Workplace software
(SiemensMedical solutions). Themetabolic tumor volumewas determined fromPET images placing a threshold-based three-dimen-
sional region of interest of isocontour 50% around the maximum activity of the tumor.
Tumors were allowed to reach a maximal diameter of 15 mm, according to the predefined humane endpoint. At the end of the
experiment, mice were sacrificed, xenograft tumors were explanted and subsequently weigh and radioactivity was determined.
For immunoblotting, tumors were thereafter passed through 70-mmcell strainers and lysed in 150mM lysis buffer. Tumor tissue sam-
ples for IHC were fixed in 4% PFA.
For immunohistochemistry, sections were deparaffinized and rehydrated. Antigen retrieval was conducted in preheated 10 mM
citrate buffer (pH 6.0) or EDTA buffer (ph 9.0) in a pressure cooker for 7 min. Subsequently slides were incubated with anti-
SLC7A5/LAT1 antibody (Abcam EPR17573: ab208776), anti-CD98hc antibody (Santa Cruz, E-5: sc-376815), anti-CD38 antibody
(ab125038, Abcam) for 1 hour at room temperature. Signal detection was performed using the Dako REAL detection system
(DAKO, Glostrup, Denmark) according to the suppliers’ recommendations.
For all tumor growth studies, a group size of at least four animals per condition was chosen. Experiments were performed in accor-
dance with the local ethical guidelines and approved by the responsible regional authorities (Regierung von Oberbayern).
Cell surface biotinylation and extraction
MM1S cells were grown in flasks and surface proteins of a minimum of 10 million of control cells or cells treated with 1 mM lenalido-
mide for 48h were biotinylated with EZ-Link Sulfo-NHS-SS-Biotin at 4C for 30 minutes following manufacturer’s instructions (Pierce
Cell Surface Protein Isolation Kit Cat. Nr. 89881, Thermo Scienctific). Subsequently, biotinylated proteins were pulled downwith Neu-
travidin beads. Cell surface proteins were eluted in Laemmli buffer under reducing conditions and analyzed by MS.
LC-MS/MS measurements
For mass spectrometry (MS) analysis, the whole cell lysate and the cell surface enriched fraction were reduced by adding fresh di-
thiothreitol (10mM, 10min, 90C), alkylated with chloroacetamide (50mM, 30min, at room temperature in the dark) and run 1 cm into
a 4%–12% Bis-Tris NuPAGETM gel (Invitrogen). Digestion of proteins was performed using trypsin according to standard in-gel pro-
cedures. Tryptic peptides were reconstituted in 0.1% formic acid (FA) and analyzed by nanoLC-MS/MS on a Dionex Ultimate
3000 UHPLC+ system coupled to a Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). After 10 min of washing
(0.1% FA, 5 mL/min) on a trap column (75 um x 2 cm, 5 mm C18 resin; Reprosil PUR AQ, Dr. Maisch), peptides were transferred to
an analytical column (75 um x 45 cm, 3 mmC18 resin; Reprosil Gold, Dr. Maisch) and separated at 300 nL/min using a 100 min linear
gradient from 4% to 32% LC solvent B (0.1% FA, 5% dimethyl sulfoxide (DMSO) in acetonitrile) in LC solvent A (0.1% FA in 5%
DMSO). The Fusion Lumoswas operated in data dependent and positive ionizationmode.MS1 spectra were recorded in theOrbitrap
from360 to 1300m/z at a resolution of 60K (automatic gain control (AGC) target value of 4e5 charges,maximum injection time (maxIT)
of 50ms). After peptide fragmentation via higher energy collisional dissociation (normalized collision energy of 30%), MS2 spectra for
peptide identification were recorded in the Orbitrap at 30K resolution via sequential isolation of up to 20 precursors (isolation window
1.7 m/z, AGC target value of 2e5, maxIT of 50 ms, dynamic exclusion of 35 s).Molecular Cell 81, 1170–1186.e1–e10, March 18, 2021 e9
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Peptide and protein identification and quantification in the cell surface fraction andwhole cell lysate were performed usingMaxQuant
(v1.6.0.16) by searching theMS2 spectra against the SwissProt database (42,271 entries, downloaded on 07.02.2018) supplemented
with common contaminants. Lys0/Arg0 and Lys6/Arg10 were specified as metabolic labels. Thematch-between-runs algorithm was
enabled. All other search parameters were left as default. Protein intensities were computed as the sum of the area-under-the-curve
of chromatographic elution profiles of peptides assigned to the proteins. Protein intensities in the cell surface fraction were normal-
ized for SILAC mixing errors based on the total sums of peptide intensities in the light and heavy channel of the whole cell lysate. For
calculation of normalization factors only peptides which were quantified in both channels were considered. Batch correction across
the three MS injections of the cell surface fraction was performed by row-wise normalization (Zecha et al., 2018) under the premise
that the sum of the light and heavy SILAC channel should be the same for a protein across all three MS injections. Before further data
analysis using the Perseus software suite (v.1.6.2.3), hits to the reverse and contaminant databases and proteins with less than 2
unique peptides were removed. The enrichment of surface proteins was verified by performing a rank-based 1D functional enrich-
ment (Cox and Mann, 2012) using gene ontology cellular component (GOCC) annotations and protein intensity ratios of the surface
fraction to the whole cell lysate. Results were corrected for multiple testing applying 1% false discovery rate (FDR) using the Benja-
mini-Hochbergmethod. Proteins significantly regulated by lenalidomide in the cell surface fraction were determined using log2 trans-
formed intensities and an unpaired, two-sided Student’s t test, assuming equal variances, and requiring a valid quantification in both
SILAC channels in at least 2 replicates. Instead of choosing a fixed p value cut-off for the determination of statistical significance, the
cut-off was adjusted on the fold-change level in a data-driven way. For this, the constant S0, which accounts for differing variances
across the intensity range of measured values and adapts the significance cut-off of statistical analyses accordingly, was calculated
in R v.3.4.1 using the function ‘‘samr’’ (S0 = 0.4). Further, the result was corrected for multiple testing at 5% FDR. For mapping of
potential interaction partners of CRBN to proteins identified in the surface enriched sample, raw data of CRBN interaction experi-
ments published previously (Eichner et al., 2016) were re-searched usingMaxQuant as described abovewith followingmodifications:
No metabolic labels were specified. Instead, the LFQ algorithm was enabled, but normalization was skipped. Proteins showing an at
least 8-fold intensity increase in the sample containing tagged CRBN compared to untagged CRBN or the empty vector were consid-
ered to be potential interaction partners of CRBN. Mapping was performed based on the first gene name in each protein group.
MS data availability
The MS proteomics raw data and MaxQuant search results have been deposited to the ProteomeXchange Consortium (http://www.
proteomexchange.org/) via the PRIDE partner repository with the dataset identifier PXD018244.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses of the results were performed by Student’s t test, one-sample t test or one-way ANOVA, according to assump-
tions of the test, using GraphPad Prism software as indicated in the figure legends. Statistical analysis of relative ratios was per-
formed using one-sample t tests with hypothetical means of 1.0. The error bars shown in the figures and supplementary figures
represent the mean ± SD. The p values are presented in the figure legends where a statistically significant difference was found:
*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. n indicates the number of independent biological replicates of an experiment.e10 Molecular Cell 81, 1170–1186.e1–e10, March 18, 2021
